August 13, 2009 (FinancialWire) — Hana Biosciences (NASDAQ: HNAB)  has achieved its enrollment goal of 56 evaluable subjects in the pivotal Phase 2 rALLy clinical trial for Marqibo(r) (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia in second relapse. Hana announced in June 2009, during the 44th Annual ASCO Meeting, that ten subjects, or 30 percent, of the first 33 evaluable subjects achieved a CR or CRi. Data presented at ASCO also showed encouraging preliminary response duration and overall survival data, as well as a predictable safety profile with no unexpected toxicity. Hana expects the final patient data to be available by year-end and, assuming positive results, plans to file its NDA seeking accelerated approval in the first half of 2010.

“We are grateful to our study subjects, their families, and the treating physicians for helping Hana achieve this important milestone,” said Anne Hagey, M.D., chief medical officer of Hana Biosciences. “This accomplishment sets the stage for further data analysis, data dissemination, and regulatory submissions intended to make Marqibo available to more patients with leukemia.”

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.